# Cotadutide

Canonical source: https://retacompare.com/encyclopedia/cotadutide

Once-daily dual GLP-1 / glucagon receptor agonist.

Reference facts

Also known asMEDI0382CategoryGLP-1 & MetabolicMechanism of actionOnce-daily dual GLP-1 / glucagon receptor agonist.TargetsGLP-1R, GCGRIndications under research or approvedType 2 Diabetes, MASH (development paused)Regulatory status (reference entry)Investigational (Phase 2 paused 2023)Half-life~12 hoursSequenceHSQGTFTSDYSKYLDEEAVRLFIEWLKNGGPSSGAPPPSSequence notesDual GLP-1 / glucagon agonist with palmitic acid attachment.Molecular weight (Da)4300Originator / sponsorAstraZeneca / MedImmuneFirst reported2018
    Primary References

Cotadutide Phase 2 hepatic lipid, Lancet GH 2022


    Explore research articles about Cotadutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Cotadutide Phase 2 hepatic lipid, Lancet GH 2022: https://pubmed.ncbi.nlm.nih.gov/35114152/